Clinical trials: Keratoconjunctivitis
Ectropion
Hyaluronic Acid Gels for Lower Lid Retraction
Lid retraction is a difficult problem encountered in oculofacial plastic surgery. It can result from previous surgery, radiotherapy or cicatrizing disease or it may be idiopathic.
- Trial name
- NCT01838252
- Testing
- Hyaluronic acid, Saline
- Where
- United States
- Sponsor
- University of California, Los Angeles
Keratoconjunctivitis Sicca
Omega-3 Fatty Acid Supplements and Dry Eye
Omega-3 fatty acids have been associated with a decline in inflammation. As dry eye disease is associated with inflammation of the ocular surface (DEWS report, Ocular Surface, 2007), the investigators hypothesize that the omega-3…
- Trial name
- NCT01213342
- Testing
- Omega-3 Fatty Acid, Soybean Soft Gels
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ohio State University
Neurotrophic Ulcer, Neurotrophic Keratitis
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
Neurotrophic keratitis (NK) is a condition where the cornea, or clear outer covering of the eye, has reduced sensation due to a variety of reasons.
- Conditions
- Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis
- Trial name
- NCT04573647
- Testing
- Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sight Medical Doctors PLLC
Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.
- Conditions
- Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis
- Trial name
- KRONOS (NCT03379311)
- Testing
- AK002
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allakos Inc.
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Dry Eye Syndromes
3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
This study is a prospective, multicentre, parallel-group, active-controlled, non-inferiority study conducted in adult patients with moderate-to-severe dry eye disease (DED) related to keratitis or keratoconjunctivitis.
- Trial name
- ALHENA (NCT04685109)
- Testing
- Alocross 0.2% Unit Dose, Vismed
- Where
- 6 sites in France
- Volunteers
- 80 people
- Sponsor
- Santen SAS
Vernal Keratoconjunctivitis
A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis
To evaluate the efficacy and safety of 0.1% tacrolimus combined with loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) in vernal keratoconjunctivitis (VKC) patients resistant to conventional treatment.
- Trial name
- NCT03464435
- Testing
- Tacrolimus
- Volunteers
- 20 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Dry Eye
A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
Objectives: Primary To determine the safety and tolerability of escalating doses of RU-101 for 4 weeks in patients with severe dry eye Secondary To explore the efficacy of RU-101 To explore optimal endpoints for future studies
- Trial name
- NCT01843894
- Testing
- RU-101
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- R-Tech Ueno, Ltd.
Keratoconjunctivitis Sicca
A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
- Trial name
- NCT00201981
- Testing
- Rebamipide 1%, Rebamipide 2%
- Where
- 63 sites in United States
- Volunteers
- 755 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Keratoconjunctivitis, Conjunctivitis
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis
- Trial name
- NCT00567918
- Testing
- FK506
- Where
- 8 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Viral Conjunctivitis
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
- Trial name
- NCT01977443
- Testing
- APD-209 Eye drops
- Where
- 10 sites in Germany, Poland and 1 more
- Volunteers
- 47 people
- Sponsor
- Adenovir Pharma AB
Superior Limbic Keratoconjunctivitis, Dry Eye Syndromes
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders
Dry eye disease, ocular graft-versus-host disease (GVHD), and superior limbic keratoconjunctivitis (SLK) are all ocular surface disorders which mostly involve the outer surface of the eye.
- Conditions
- Superior Limbic Keratoconjunctivitis, Dry Eye Syndromes, Graft Vs Host Disease
- Trial name
- NCT03731624
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Superior Limbic Keratoconjunctivitis
The Pathogenesis of Superior Limbic Keratoconjunctivitis
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown.
- Trial name
- NCT00167050
- Where
- Taiwan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in…
- Trial name
- NCT02798289
- Testing
- Oculeve Intranasal Neurostimulator
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Oculeve, Inc.
Keratoconjunctivitis Sicca
Study of Rebamipide Eye Drops to Treat Dry Eye
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
- Trial name
- NCT00201955
- Testing
- Rebamipide 1%, Rebamipide 2%
- Where
- 60 sites in United States
- Volunteers
- 762 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dry Eye, Keratoconjunctivitis Sicca
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
- Trial name
- NCT05918406
- Testing
- Nasal Guide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Oyster Point Pharma, Inc.
Keratoconjunctivitis, Conjunctivitis
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
To investigate the efficacy and safety of FK506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis
- Trial name
- NCT00567762
- Testing
- FK506
- Where
- 8 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Astellas Pharma Inc